Ischemic heart disease
Conditions
Interventions
Once-daily dosing of pravastatin 10mg and ezetimibe 10mg. If the LDL-C value in 4 weeks has not reached less than 100mg/dL, the titlation of statin dose is repeated at every visit to achieve to the l
Sponsors
Nippon Medical School
Kansai Rosai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Coronary revascularization patients with drug-eluting stent whose LDL-C value is controlled to less than 140mg/dL over 100mg/dL by statin medications, and also whose plaque was observed with angioscopy. 2) Patients less than 85 over 25 years old 3) Unquestioned gender 4) Hospitalization, outpatient unquestioned
Exclusion criteria
Exclusion criteria: 1. Patients within 72 hr after the incidence of acute myocardial infarction. 2. Patients with marked stenosis in the main coronary artery 3. Patients with serum creatinine over 2.0mg/dL. 4. The patients with heart failure which is over NYHA cardiac function classification3, or ejection fraction is less than 40%. 5. The patients with secondary hypercholesterolemia 6. The patients who were daily treated with over 10mg of atorvastatin or 2mg of pitavastatin or 2.5mg of rosuvastatin, and the combination of ezetimibe and statin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The color changes of coronary plaque in 12 months after revascularization with DES | — |
Secondary
| Measure | Time frame |
|---|---|
| Grade change of neointimal SMC in culprit lesion with DES The color change of coronary plaque in non culprit lesion with DES Thrombosis in culprit lesion with DES | — |
Countries
Japan
Contacts
Public ContactInami Shigenobu
Nippon Medical School Department of cardiovascular medicine
Outcome results
None listed